4 Pictures Every Valeant-Salix Investor Should See

Canada's Valeant Pharmaceuticals International Inc VRX has agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd SLXP in an all-cash deal valued at about $10.1 billion. Valeant will pay $158.00 a share for the merger, which is expected to more than $500 million in annual cost savings within six months. The transaction is expected to close in the second quarter of 2015.

Evercore ISI analyst Umer Raffat revealed a deep slideshow presentation regarding the companies on Monday.